243 filings
Page 3 of 13
8-K
tluegslt
14 Dec 22
Syndax Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
4:31pm
8-K
gnzwq7l43z4njt1fv
7 Dec 22
Entry into a Material Definitive Agreement
5:06pm
424B5
3ht0lqd scb96r6
7 Dec 22
Prospectus supplement for primary offering
4:04pm
424B5
ge38s
6 Dec 22
Prospectus supplement for primary offering
5:07pm
8-K
h2b9indx8g
5 Dec 22
Syndax Pharmaceuticals Announces Appointment of Steve Sabus as Chief Commercial Officer
7:08am
8-K
b20lhakrmm48p
3 Nov 22
Syndax Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Clinical and Business Update
4:03pm
8-K
h943yrapgjw 6mwu5
23 Sep 22
Termination of a Material Definitive Agreement
4:05pm
8-K
x4ka ayk1vqmsu
8 Aug 22
Syndax Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Clinical and Business Update
4:04pm
8-K
2skq2d0zcl487z7q5kq
13 Jun 22
Syndax Pharmaceuticals Announces Appointment of
7:32am
8-K
68ri5
11 May 22
Submission of Matters to a Vote of Security Holders
4:02pm
8-K
3vbr5e
9 May 22
Syndax Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical and Business Update
12:00am
DEFA14A
mrkouob 2ovodd
30 Mar 22
Additional proxy soliciting materials
4:03pm
S-8
9s01yq0n9rr1rpv8
1 Mar 22
Registration of securities for employees
5:30pm
8-K
a5mu9xad10fof 9qgh
1 Mar 22
Syndax Pharmaceuticals Reports Fourth Quarter 2021 Financial Results and Provides Clinical and Business Update
12:00am
8-K
sz4zwaw4dq7 1j4ro
24 Feb 22
Departure of Directors or Certain Officers
7:03am